Graden af disse bivirkninger var typisk mild til moderat, og der var ingen forskelle mellem alder, race eller køn med hensyn til incidens af bivirkningerne.
In general, when adverse reactions occurred, onset was in the first week of therapy; severity was generally mild to moderate and there were no differences by age, race or gender with regard to the incidence of adverse reactions.